Table 2.
Consumption of medicines from the fourth level pharmacological groups of Group A, Group C, and Group N.
| % (N) | |
|---|---|
| Group A | |
| A01A stomatological preparations | 0.2% (2) |
| A02A antacids | 0.3% (3) |
| A02B drugs for peptic ulcer and gastro-oesophageal reflux disease | 46.4% (501) |
| A03A drugs for functional gastrointestinal disorders | 1.2% (13) |
| A03B belladonna and derivatives, plain | 0.3% (3) |
| A03F propulsives | 2.1% (23) |
| A05A bile therapy | 0.1% (1) |
| A06A drugs for constipation | 1.3% (14) |
| A07A intestinal antiinfectives | 0.1% (1) |
| A07D antipropulsives | 0.3% (3) |
| A07E intestinal antiinflammatory agents | 0.7% (8) |
| A07F antidiarrheal microorganisms | 0.2% (2) |
| A09A digestives, incl. Enzymes | 0.4% (4) |
| A10A insulins and analogues | 7.6% (83) |
| A10B blood glucose lowering drugs, excl. Insulins | 37.3% (403) |
| A11A multivitamins, combinations | 0.1% (1) |
| A11C vitamin a and d, incl. Combinations of the two | 4.8% (52) |
| A11D vitamin b1, plain and in combination with vitamin b6 and b12 | 1.7% (18) |
| A11E vitamin b-complex, incl. Combinations | 0.3% (3) |
| A11G ascorbic acid (vitamin c), incl. Combinations | 0.1% (1) |
| A12A calcium | 6.4% (69) |
| A12C other mineral supplements | 1.6% (17) |
| A13A tonics | 0.1% (1) |
| Group C | |
| C01A cardiac glycosides | 2.3% (25) |
| C01B antiarrhythmics, class i and iii | 3.9% (42) |
| C01D vasodilators used in cardiac diseases | 4.9% (53) |
| C01E other cardiac preparations | 5.8% (62) |
| C02A antiadrenergic agents, centrally acting | 1.9% (20) |
| C02C antiadrenergic agents, peripherally acting | 0.2% (2) |
| C03A low-ceiling diuretics, thiazides | 0.2% (2) |
| C03B low-ceiling diuretics, excl. Thiazides | 9.2% (99) |
| C03C high-ceiling diuretics | 18.7% (201) |
| C03D potassium-sparing agents | 3.2% (35) |
| C03E diuretics and potassium-sparing agents in combination | 1.6% (17) |
| C04A peripheral vasodilators | 3.2% (35) |
| C05A agents for treatment of hemorrhoids and anal fissures for topical use | 0.2% (2) |
| C05B antivaricose therapy | 0.6% (6) |
| C05C capillary stabilizing agents | 7.2% (77) |
| C07A beta blocking agents | 26.7% (289) |
| C07B beta blocking agents and thiazides | 0.2% (2) |
| C07C beta blocking agents and other diuretics | 0.1% (1) |
| C08C selective calcium channel blockers with mainly vascular effects | 14.8% (159) |
| C08D selective calcium channel blockers with direct cardiac effects | 1.9% (20) |
| C08G calcium channel blockers and diuretics | 0.1% (1) |
| C09A angiotensin-converting-enzyme inhibitors, plain | 16.4% (176) |
| C09B angiotensin-converting-enzyme inhibitors, combinations | 14.5% (156) |
| C09C angiotensin II receptor blockers, plain | 18.3% (198) |
| C09D angiotensin II receptor blockers, combinations | 21.3% (230) |
| C09X other agents acting on the renin-angiotensin system | 0.2% (2) |
| C10A lipid modifying agents, plain | 59.7% (644) |
| C10B lipid modifying agents, combinations | 3.5% (38) |
| Group N | |
| N01A anesthetics, general | 0.2% (2) |
| N02A opioids | 8.2% (88) |
| N02B other analgesics and antipyretics | 13.2% (143) |
| N02C antimigraine preparations | 0.1% (1) |
| N03A antiepileptics | 9.3% (100) |
| N04B dopaminergic agents | 2.9% (31) |
| N05A antipsychotics | 4.5% (48) |
| N05B anxiolytics | 38.6% (406) |
| N05C hypnotics and sedatives | 4.6% (50) |
| N06A antidepressants | 22.4% (242) |
| N06B psychostimulants, agents used for adhd and nootropics | 2.6% (28) |
| N06D anti-dementia drugs | 4.3% (46) |
| N07A parasympathomimetics | 0.1% (1) |
| N07C antivertigo preparations | 8.1% (87) |
| N07X other nervous system drugs | 0.1% (1) |